UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 5.

Salazar, F; Molina, M A; Sanchez-Ronco, M; Moran, T; Ramirez, J L; Sanchez, J M; Stahel, R; Garrido, P; Cobo, M; Isla, D; Bertran-Alamillo, J; Massuti, B; Cardenal, F; Manegold, C; Lianes, P; Trigo, J M; Sanchez, J J; Taron, M; Rosell, R (2011). First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer, 72(1):84-91.

Felip, E; Gridelli, C; Baas, P; Rosell, R; Stahel, R (2011). Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Annals of Oncology, 22(7):1507-1519.

Stahel, R; Baas, P; Faivre-Finn, C; Dooms, C; Passlick, B; Mazières, J; Cappuzzo, F; Früh, M; Sorensen, J B; Blackhall, F; Taron, M; Gridelli, C; O'Byrne, K; Rosell, R (2010). Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). Lung Cancer, 68(1):121-124.

Pirker, R; Herth, F J F; Kerr, K M; Filipits, M; Taron, M; Gandara, D; Hirsch, F R; Grunenwald, D; Popper, H; Smit, E; Dietel, M; Marchetti, A; Manegold, C; Schirmacher, P; Thomas, M; Rosell, R; Cappuzzo, F; Stahel, R (2010). Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. Journal of Thoracic Oncology, 5(10):1706-1713.

Rosell, R; Manegold, C; Moran, T; Garrido, P; Blanco, R; Lianes, P; Stahel, R; Trigo, J M; Wei, J; Taron, M (2008). Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 9(Supplement 2):S76-S82.

This list was generated on Tue Jul 25 09:23:20 2017 CEST.